Infinity Pharmaceuticals, Inc.

OTCPK:INFI.Q Stock Report

Market Cap: US$90.0

Infinity Pharmaceuticals Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Seth Tasker

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure7.7yrs
CEO ownershipn/a
Management average tenureno data
Board average tenure6yrs

Recent management updates

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Recent updates

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Nov 10
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

Infinity Pharmaceuticals: Waiting For A Deal

Sep 08

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

May 23
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Invest In Growth?

We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Dec 29
We're Hopeful That Infinity Pharmaceuticals (NASDAQ:INFI) Will Use Its Cash Wisely

Investigating Infinity Pharmaceuticals

Nov 25

Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Jul 18
Infinity Pharmaceuticals (NASDAQ:INFI) Is In A Good Position To Deliver On Growth Plans

Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Jun 03
Increases to Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) CEO Compensation Might Cool off for now

Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Apr 13
Is Infinity Pharmaceuticals (NASDAQ:INFI) In A Good Position To Deliver On Growth Plans?

Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Feb 19
Are Institutions Heavily Invested In Infinity Pharmaceuticals, Inc.'s (NASDAQ:INFI) Shares?

Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Jan 15
Can You Imagine How Jubilant Infinity Pharmaceuticals' (NASDAQ:INFI) Shareholders Feel About Its 147% Share Price Gain?

Infinity Pharma to start new registration-enabling eganelisib study in urothelial cancer

Jan 06

Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Dec 11
Will Infinity Pharmaceuticals (NASDAQ:INFI) Spend Its Cash Wisely?

Infinity Pharma slides after eganelisib data presentation at Breast Cancer Symposium

Dec 09

Infinity Pharmaceutical Reaching Vital New Staging Posts

Dec 01

CEO Compensation Analysis

How has Seth Tasker's remuneration changed compared to Infinity Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2023n/an/a

-US$41m

Mar 31 2023n/an/a

-US$43m

Dec 31 2022n/an/a

-US$44m

Sep 30 2022n/an/a

-US$47m

Jun 30 2022n/an/a

-US$47m

Mar 31 2022n/an/a

-US$46m

Dec 31 2021n/an/a

-US$45m

Sep 30 2021n/an/a

-US$44m

Jun 30 2021n/an/a

-US$43m

Mar 31 2021n/an/a

-US$41m

Dec 31 2020US$1mUS$386k

-US$40m

Sep 30 2020n/an/a

-US$41m

Jun 30 2020n/an/a

-US$43m

Mar 31 2020n/an/a

-US$44m

Dec 31 2019US$653kUS$368k

-US$47m

Sep 30 2019n/an/a

-US$44m

Jun 30 2019n/an/a

-US$19m

Mar 31 2019n/an/a

-US$16m

Dec 31 2018n/an/a

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$31m

Mar 31 2018n/an/a

-US$41m

Dec 31 2017US$1mUS$320k

-US$42m

Compensation vs Market: Insufficient data to establish whether Seth's total compensation is reasonable compared to companies of similar size in the US market.

Compensation vs Earnings: Seth's compensation has increased whilst the company is unprofitable.

CEO

Seth Tasker (44 yo)

7.7yrs

Tenure

US$1,435,444

Compensation

Mr. Seth A. Tasker, J.D., has been Senior Vice President, General Counsel and Secretary at Infinity Pharmaceuticals, Inc. since December 2019 and has been its CEO since September 1, 2023 and had been its C...

Board Members

NamePositionTenureCompensationOwnership
Anthony Evnin
Independent Director17.5yrsUS$93.08k0.24%
$ 0.2
Norman Selby
Lead Independent Director12yrsUS$125.82k0.017%
$ 0.01
David Beier
Independent Director5.9yrsUS$85.58k0.0097%
$ 0.009
Roy Steven Herbst
Member of Scientific Advisory Board6yrsno datano data
David Munn
Member of Scientific Advisory Board6yrsno datano data
F. Hodi
Member of Scientific Advisory Board6yrsno datano data
Richard B. Gaynor
Independent Director4yrsUS$83.08k0%
$ 0
Dmitry Gabrilovich
Member of Scientific Advisory Board6yrsno datano data
Jeffery Kutok
Chairman of Scientific Advisory Board4yrsUS$759.67kno data
Samuel Agresta
Chair of Clinical Advisory Boardno dataUS$73.08k0.012%
$ 0.01
Toni Choueiri
Member of Clinical Advisory Boardno datano datano data
Michael Postow
Member of Clinical Advisory Boardno datano datano data

6.0yrs

Average Tenure

71yo

Average Age

Experienced Board: INFI.Q's board of directors are considered experienced (6 years average tenure).

Simply Wall St™
Simply Wall Street Pty Ltd
Level 7, 320 Pitt Street, Sydney
Download on the App StoreGet it on Google Play
Popular Markets
USAUUKINCAZA
About UsCareersPlansLogin
Help CenterLatest CoveragePodcastsAffiliate ProgramBusiness & Enterprise
Financial Services GuideTerms and ConditionsPrivacy PolicyLogos provided by Clearbit
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.